Skip to main content
NCBI home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 2003 Dec;88(12):1065–1069. doi: 10.1136/adc.88.12.1065

The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area

S Deshpande 1, V Northern 1
PMCID: PMC1719378  PMID: 14670770

Abstract

Aims: To describe the clinical and health economic impact of respiratory syncytial virus (RSV) disease in children under 2 years of age.

Methods: Hospitalised children less than 2 years of age with a respiratory illness were studied over three consecutive RSV seasons (1996–99).

Results: The rates (per 1000 infants under 1 year of age) of hospitalisations from bronchiolitis and RSV illness were 30.8 and 24.4 respectively. The rates of death, intensive care admission, and need for ventilatory assistance during RSV related hospitalisation were 0.2%, 2.7%, and 1.5% respectively. From a cohort of 841 preterm infants, 6.3% had an RSV related hospitalisation during the study period, with the rate rising to 9.2% among those who were either born before 36 weeks gestation and were under 6 months of age at the onset of the RSV seasons, or were less than 2 years of age with chronic lung disease needing home oxygen therapy. Eight of 25 children on home oxygen therapy had RSV related rehospitalisation. Need for assisted ventilation during the neonatal period and discharge home on oxygen therapy were significantly associated with the risk of subsequent RSV related hospitalisation in preterm infants less than 6 months of age. The direct health authority cost of all RSV hospitalisations was £542 203, while the currently recommended immunoprophylaxis for the high risk infants would have cost £652 960.

Conclusions: Preterm infants receiving assisted ventilation and those on home oxygen therapy are particularly at risk of RSV related hospitalisation. Serious adverse outcomes are however uncommon even among these high risk infants.

Full Text

The Full Text of this article is available as a PDF (216.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Briggs A. Economic evaluation and clinical trials: size matters. BMJ. 2000 Dec 2;321(7273):1362–1363. doi: 10.1136/bmj.321.7273.1362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Clark S. J., Beresford M. W., Subhedar N. V., Shaw N. J. Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort. Arch Dis Child. 2000 Oct;83(4):313–316. doi: 10.1136/adc.83.4.313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Greenough A., Alexander J., Burgess S., Chetcuti P. A. J., Cox S., Lenney W., Turnbull F., Shaw N. J., Woods A., Boorman J. Home oxygen status and rehospitalisation and primary care requirements of infants with chronic lung disease. Arch Dis Child. 2002 Jan;86(1):40–43. doi: 10.1136/adc.86.1.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hall C. B. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001 Jun 21;344(25):1917–1928. doi: 10.1056/NEJM200106213442507. [DOI] [PubMed] [Google Scholar]
  5. Joffe S., Escobar G. J., Black S. B., Armstrong M. A., Lieu T. A. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics. 1999 Oct;104(4 Pt 1):894–899. doi: 10.1542/peds.104.4.894. [DOI] [PubMed] [Google Scholar]
  6. Joffe S., Ray G. T., Escobar G. J., Black S. B., Lieu T. A. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999 Sep;104(3 Pt 1):419–427. doi: 10.1542/peds.104.3.419. [DOI] [PubMed] [Google Scholar]
  7. Martin A. J., Gardner P. S., McQuillin J. Epidemiology of respiratory viral infection among paediatric inpatients over a six-year period in north-east England. Lancet. 1978 Nov 11;2(8098):1035–1038. doi: 10.1016/s0140-6736(78)92351-6. [DOI] [PubMed] [Google Scholar]
  8. Moler F. W. RSV immune globulin prophylaxis: is an ounce of prevention worth a pound of cure? Pediatrics. 1999 Sep;104(3 Pt 1):559–560. doi: 10.1542/peds.104.3.559. [DOI] [PubMed] [Google Scholar]
  9. Navas L., Wang E., de Carvalho V., Robinson J. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr. 1992 Sep;121(3):348–354. doi: 10.1016/s0022-3476(05)90000-0. [DOI] [PubMed] [Google Scholar]
  10. Shay D. K., Holman R. C., Newman R. D., Liu L. L., Stout J. W., Anderson L. J. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999 Oct 20;282(15):1440–1446. doi: 10.1001/jama.282.15.1440. [DOI] [PubMed] [Google Scholar]
  11. Simoes E. A., Sondheimer H. M., Top F. H., Jr, Meissner H. C., Welliver R. C., Kramer A. A., Groothuis J. R. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr. 1998 Oct;133(4):492–499. doi: 10.1016/s0022-3476(98)70056-3. [DOI] [PubMed] [Google Scholar]
  12. Sims D. G., Downham M. A., McQuillin J., Gardner P. S. Respiratory syncytial virus infection in north-east England. Br Med J. 1976 Nov 6;2(6044):1095–1098. doi: 10.1136/bmj.2.6044.1095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Spencer N., Logan S., Scholey S., Gentle S. Deprivation and bronchiolitis. Arch Dis Child. 1996 Jan;74(1):50–52. doi: 10.1136/adc.74.1.50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Thomas M., Bedford-Russell A., Sharland M. Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin. Arch Dis Child. 2000 Aug;83(2):122–127. doi: 10.1136/adc.83.2.122. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES